TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32877411

Group type: EXPERIMENTAL
Intervention: Adherence to PAD monitoring (pain monitoring)
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Adherence to PAD monitoring
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Non-adherence to PAD monitoring
Number of subjects: 1323
Study: 32877524

Group type: EXPERIMENTAL
Intervention: 177Lu-lilotomab satetraxetan
Number of subjects: 74
Study: 32877573

Group type: EXPERIMENTAL
Intervention: UA-lowering drugs
Number of subjects: 211
Study: 32877583

Group type: EXPERIMENTAL
Intervention: Capmatinib
Number of subjects: 364
Study: 32877600

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 8 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 4 weeks)
Number of subjects: 58
Study: 32878377

Group type: EXPERIMENTAL
Intervention: 3 months treatment (defocused communication and behavioural techniques)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 24
Study: 32878566

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (standard- and low-dose, ≥3× per week)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control group (not specified if treated with any other intervention)
Number of subjects: 315
Study: 32878604

Group type: EXPERIMENTAL
Intervention: Visit-to-visit fasting plasma glucose (FPG) variability
Number of subjects: 437
Study: 32878614

Group type: EXPERIMENTAL
Intervention: Participation and Environment Measure (post-PICU dissatisfaction assessment)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Home environmental support and participation-focused strategies with PICU-based rehabilitation services
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Caregiver stress and functional performance
Number of subjects: 170
Study: 32878766

Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg combined with gemcitabine (1,000 mg/m2) and cisplatin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DKN-01 600 mg
Number of subjects: 51
Study: 32879034

Group type: EXPERIMENTAL
Intervention: Continuous-in-time vital signs information
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Combination of vital sign information with static clinical data
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Machine learning models
Number of subjects: 284
Study: 32879326

Group type: EXPERIMENTAL
Intervention: Crolibulin (13-24 mg/m2)
Number of subjects: 11
Study: 32879339

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire (score ≥ 3 of 8)
Number of subjects: 290

Group type: COMPARATOR
Intervention: STOP-Bang questionnaire (score < 3 of 8)
Number of subjects: 290
Study: 32879938

Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation (7 biomarkers for type 1 diabetes, 24 biomarkers for type 2 diabetes)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Biomarkers of inflammation (6 biomarkers: CD5, CCL23, CST5, IL-10RB, PD-L1, TNFRSF9)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers
Number of subjects: 456
Study: 32879974

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using VISITAG SURPOINT with specific targets (≥550 on anterior wall; ≥400 on posterior wall) and intertag distance (≤6 mm)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Number of subjects: 340
Study: 32880091

Group type: EXPERIMENTAL
Intervention: Immediate preoperative renal artery embolization (IPRAE)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (no IPRAE)
Number of subjects: 145
Study: 32880104

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) + Treatment-as-Usual (TAU)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Impulsive Lifestyle Counselling (ILC) + Treatment-as-Usual (TAU)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) + Standard Maintenance (SM)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Driving Whilst Intoxicated (DWI) programme + incarceration
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Social Problem-Solving (SPS) + Psychoeducation (PE)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Psychosocial Risk Management (PSRM)
Number of subjects: 605
Study: 32880105

Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg/day)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Desipramine (250 to 300 mg/day)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Nortriptyline (25 to 75 mg/day)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg/day)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 416
Study: 32881280

Group type: EXPERIMENTAL
Intervention: ctDNA analysis with therapy matched to ctDNA alterations (N=33 patients)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Higher ctDNA maximum mutation allele frequency
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ctDNA and tissue genomic results
Number of subjects: 105
Study: 32881586

Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment
Number of subjects: 0
Study: 32881886

Group type: EXPERIMENTAL
Intervention: L-Arginine (100 mg/kg single dose)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: L-Arginine (100 mg/kg three times daily po X 6 weeks)
Number of subjects: 3
Study: 32882243

Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 risk assessment calculator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 parameters (BNP/NT-proBNP, 6MWD, FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 with missing variables (heart rate, SBP, eGFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2
Number of subjects: 0
Study: 32882399

Group type: EXPERIMENTAL
Intervention: Beta-blocker intake before exposure to loud noise (∼100 dB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Beta-blocker intake before simulated diving (face immersion in cold water)
Number of subjects: 23
Study: 32882958

Group type: EXPERIMENTAL
Intervention: Oral health activities incorporated into pediatric well-child visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard pediatric well-child visits without oral health activities)
Number of subjects: 0
Study: 32882978

Group type: EXPERIMENTAL
Intervention: Regular meals defined by dietary quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mReg scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 0
Study: 32883179

Group type: EXPERIMENTAL
Intervention: Recognition subtests for the Repeatable Battery for the Assessment of Neuropsychological Status
Number of subjects: 0
Study: 32883192

Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low-intensity training
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Conventional interventions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Stepping activity
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Age and baseline function
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Participants with smallest gains
Number of subjects: 144
Study: 32883248

Group type: EXPERIMENTAL
Intervention: Qualitative suggestions for improving HIV prevention efforts
Number of subjects: 288
Study: 32883297

Group type: EXPERIMENTAL
Intervention: NMES of the vastus lateralis and rectus femoris during stance
Number of subjects: 1

Group type: COMPARATOR
Intervention: Current Ankle-Foot Orthosis (AFO)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Unassisted Exoskeleton
Number of subjects: 1

Group type: COMPARATOR
Intervention: NMES of the vastus lateralis
Number of subjects: 1
Study: 32883677

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 0
Study: 32883728

Group type: EXPERIMENTAL
Intervention: CT index test in the neutral position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT index test with stress manoeuvres (external rotation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT index test with stress manoeuvres (dorsiflexion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot and Ankle Ability Measure questionnaire
Number of subjects: 0
Study: 32883871

Group type: EXPERIMENTAL
Intervention: CD19-28ζ CAR T-cell therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Monitoring with formal echocardiograms and cardiac biomarkers (troponin and proBNP)
Number of subjects: 52
Study: 32884017

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study: 32884151

Group type: EXPERIMENTAL
Intervention: AAVrh8 gene therapy injected into the thalamus and deep cerebellar nuclei
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAVrh8 gene therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated cats
Number of subjects: 0
Study: 32884231

Group type: EXPERIMENTAL
Intervention: Topical Latanoprost 0.005%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Topical Timolol Maleate 0.5%
Number of subjects: 36
Study: 32884828

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A) using 2-mL dilution (500 U/2-mL)
Number of subjects: 0
Study: 32885090

Group type: EXPERIMENTAL
Intervention: Healthy Weight Coaching (HWC) - a 12-month web-based intervention
Number of subjects: 0
Study: 32885091

Group type: EXPERIMENTAL
Intervention: Isocaloric high-GI Mediterranean-style healthy eating pattern (MED-HEP) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric low-GI Mediterranean-style healthy eating pattern (MED-HEP) for 12 weeks
Number of subjects: 0
Study: 32885133

Group type: EXPERIMENTAL
Intervention: MFGM-enriched bovine milk beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator beverage (nonfat dairy powder, coconut and palm oils, and soy phospholipids)
Number of subjects: 0
Study: 32885187

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary geriatric assessment in the ED setting
Number of subjects: 0
Study: 32885188

Group type: EXPERIMENTAL
Intervention: BetterBirth intervention implementing the WHO Safe Childbirth Checklist; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BetterBirth intervention; details on dosage and duration not available.
Number of subjects: 0
Study: 32885198

Group type: EXPERIMENTAL
Intervention: Positive-Minds-Strong Bodies (PM-SB) intervention consisting of cognitive behavior therapy and exercise training sessions delivered over 6 months.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PM-SB intervention
Number of subjects: 30
Study: 32885214

Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI) implementation
Number of subjects: 21
Study: 32885211

Group type: EXPERIMENTAL
Intervention: Evidence-based clinical decision support tools that integrate into the workflow and do not extend visit time
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resources that respond to family's needs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multimodal delivery options for family resources
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Addressing childhood obesity while balancing competing demands
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patient care rather than documentation and establishing sustainability plans
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multiple training methods that incorporate performance feedback
Number of subjects: 52
Study: 32885217

Group type: EXPERIMENTAL
Intervention: High scores on CFIR organizational characteristics (e.g., organizational readiness, implementation climate, organizational culture, innovation fit)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Offering health programs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Organizational factors for health programming
Number of subjects: 34
Study: 32885241

Group type: EXPERIMENTAL
Intervention: Psoriatic onycholysis (ONY)
Number of subjects: 87

Group type: COMPARATOR
Intervention: PsA group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy age-matched controls (CTRL)
Number of subjects: 87
Study: 32885254

Group type: EXPERIMENTAL
Intervention: Mid-infrared fibre evanescent wave spectroscopy
Number of subjects: 402
Study: 32885664

Group type: EXPERIMENTAL
Intervention: DNMT3A knockout in cardiomyocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (not specified)
Number of subjects: 0
Study: 32885736

Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JetStream XC atherectomy device (without considering bailout stenting as TLR)
Number of subjects: 60
Study: 32886107

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake of polyunsaturated fat
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake of fiber from grains
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Human milk exclusivity
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Frequency of direct breastfeeding per day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Maternal fiber intake from grains
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Total fiber consumption
Number of subjects: 93
Study: 32886347

Group type: EXPERIMENTAL
Intervention: Imipenem 0.5 g every 6 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Imipenem 1 g every 6 hours
Number of subjects: 10
Study: 32886753

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (15-21 mg/kg cumulative doses, administered as 1 to 5 once-weekly subcutaneous infusions)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab (15-20 mg/kg single doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 66
Study: 32886914

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels measured daily in the first 3 days post-aSAH
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels in infection-free patients
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels post-DCI
Number of subjects: 132
Study: 32887239

Group type: EXPERIMENTAL
Intervention: Perceptions, attitudes, and behaviors regarding obesity management among people with obesity
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' perceptions and attitudes towards obesity management
Number of subjects: 1500
Study: 32887588

Group type: EXPERIMENTAL
Intervention: Visit-to-visit HbA
Number of subjects: 420
Study: 32887637

Group type: EXPERIMENTAL
Intervention: Baby Newsletter intervention (8 newsletters)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (parents from other municipalities)
Number of subjects: 136
Study: 32887722

Group type: EXPERIMENTAL
Intervention: Ribociclib 600 mg (3 weeks on, 1 week off) plus Fulvestrant 500 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg plus Buparlisib 30 mg plus Fulvestrant 500 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg plus Alpelisib (no RP2D determined)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ribociclib plus Fulvestrant (general)
Number of subjects: 70
Study: 32888036

Group type: EXPERIMENTAL
Intervention: Serum BMP-7
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Serum sclerostin
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Serum DKK-1
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Serum BMP-7 in active disease (ASDAS with CRP ≥1.3)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Serum BMP-7 with TNF inhibitor (TNFi) use
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Serum sclerostin change
Number of subjects: 708
Study: 32888112

Group type: EXPERIMENTAL
Intervention: HOME-CoV rule (criteria for hospitalization)
Number of subjects: 51
Study: 32888407

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 344
Study: 32888452

Group type: EXPERIMENTAL
Intervention: Venetoclax plus obinutuzumab
Number of subjects: 432

Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab
Number of subjects: 432
Study: 32888723

Group type: EXPERIMENTAL
Intervention: Consultation with complex family planning specialists
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive methods (intrauterine device and contraceptive implant)
Number of subjects: 97
Study: 32889146

Group type: EXPERIMENTAL
Intervention: Multi-target HCC panel (3 MDMs: HOXA1, EMX1, TSPYL5; B3GALT6; 2 protein markers: AFP and AFP-L3)
Number of subjects: 135

Group type: COMPARATOR
Intervention: GALAD score
Number of subjects: 135

Group type: COMPARATOR
Intervention: AFP ≥7.32 ng/mL
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Multi-target HCC panel
Number of subjects: 135

Group type: COMPARATOR
Intervention: AFP alone
Number of subjects: 135
Study: 32889525

Group type: EXPERIMENTAL
Intervention: Obese women with weight loss <5%
Number of subjects: 2071

Group type: EXPERIMENTAL
Intervention: Overweight/obese women with weight loss ≥5%
Number of subjects: 2071

Group type: EXPERIMENTAL
Intervention: Overweight and obese men
Number of subjects: 2071
Study: 32889812

Group type: EXPERIMENTAL
Intervention: COX-2 expression in squamous cell carcinomas (SCCs)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: COX-2 expression in basal cell carcinomas
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: COX-2 expression in precancerous lesions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Normal skin COX-2 expression
Number of subjects: 26
Study: 32889866

Group type: EXPERIMENTAL
Intervention: PD with PVR
Number of subjects: 840
Study: 32889978

Group type: EXPERIMENTAL
Intervention: Volume management strategies (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel methods of assessing and restoring extracellular fluid volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local protocols and programmes for volume management
Number of subjects: 0
Study: 32890108

Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 10
Study: 32890324

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) performed 2 weeks after initial TACE treatment.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 69
Study: 32890609

Group type: EXPERIMENTAL
Intervention: Surface imaging with verbal instruction and gating
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phantom studies
Number of subjects: 10
Study: 32891132

Group type: EXPERIMENTAL
Intervention: Long-term androgen treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FACS analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Age and BMI correlation
Number of subjects: 20
Study: 32891319

Group type: EXPERIMENTAL
Intervention: Single-port access laparoscopic radical hysterectomy (SPA LRH)
Number of subjects: 59
Study: 32891400

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (platelet count <150 × 10^9/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal platelet count (≥150 × 10^9/L)
Number of subjects: 0
Study: 32891715

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) treatment prior to irradiation for 24 hours
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combined in vivo treatment with FTD/TPI and radiation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Capecitabine radiochemotherapy
Number of subjects: 4
Study: 32892294

Group type: EXPERIMENTAL
Intervention: Comprehensive Complication Index (CCI)
Number of subjects: 1782
Study: 32893266

Group type: EXPERIMENTAL
Intervention: Development of cardiac myxomas in CNC patients
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Age at diagnosis of cardiac myxomas
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Occurrence of myxomas by age 30
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Frequency of CNC-related lesions
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Recurrence of myxomas
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Gender differences in recurrence rates
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Risk estimates for cardiac myxomas
Number of subjects: 319
Study: 32893393

Group type: EXPERIMENTAL
Intervention: 3 mg/kg dupilumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 mg/kg dupilumab
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: dupilumab (both doses)
Number of subjects: 40
Study: 32893720

Group type: EXPERIMENTAL
Intervention: Community-engaged stroke preparedness intervention
Number of subjects: 21497
Study: 32894059

Group type: EXPERIMENTAL
Intervention: Sepsis surveillance method
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Angus' method
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Martin's method
Number of subjects: 1352
Study: 32894185

Group type: EXPERIMENTAL
Intervention: CNCT19 CAR T therapy
Number of subjects: 22
Study: 32894453

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nutrition psychoeducation (MINP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Motivational interviewing (MI) or nutrition psychoeducation interventions (separately)
Number of subjects: 31
Study: 32894672

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiol supplements
Number of subjects: 0
Study: 32894829

Group type: EXPERIMENTAL
Intervention: Pivot Breath Sensor
Number of subjects: 234
Study: 32894869

Group type: EXPERIMENTAL
Intervention: Quantose IR test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional testing methods
Number of subjects: 100
Study: 32894868

Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in bile
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Logistic regression model for VOCs
Number of subjects: 57
Study: 32895005

Group type: EXPERIMENTAL
Intervention: Residual Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) score (RSS)
Number of subjects: 1910

Group type: COMPARATOR
Intervention: Tertile classification of RSS (0, 1-5, and >5) and post-PCI FFR (≥0.94, 0.87-0.93, and ≤0.86)
Number of subjects: 1910